AstraZeneca Global China R&D Center opens in Shanghai
The China research and development center of AstraZeneca – one of the world's leading pharmaceutical groups – officially opened in Shanghai city in East China on Oct 11.
Located in Shanghai's Jing'an district, the center will do advance R&D and clinical trials of new medicines, both from China and overseas.
AstraZeneca's R&D pipeline in China now has more than 120 projects under development.
According to company officials, the facility will increase the use of biological analysis, translational medicine, artificial intelligence, big data and other high-end technologies to help global R&D.
It will also reportedly work with top domestic medical centers, research institutions and innovative enterprises to jointly create a pharma R&D innovation ecosystem, supporting the development of new original medicines in China.
The Shanghai municipal government is understood to be sparing no efforts to develop a world-class biopharma industry cluster and AstraZeneca is partnering it to achieve that end.
In addition to the AstraZeneca Global China R&D Center, a number of other multinational pharma projects – including the BioNTech China headquarters – have also been settled in Jing'an district this year.